10:19 AM EST, 11/21/2025 (MT Newswires) -- OSR (OSRH) shares were up 32% in recent Friday trading after the company said its Vaximm subsidiary has signed a non-binding term sheet with BCM Europe to explore a potential exclusive global licensing agreement for VXM01 cancer immunotherapy platform.

The term sheet provides the parties with a six-month exclusivity period during which Vaximm and BCME intend to finalize a definitive licensing agreement, OSR said.

Under the contemplated terms, Vaximm would receive $20 million upfront and up to $815 million in milestone payments, OSR said.

Price: 0.69, Change: +0.23, Percent Change: +51.32